REFERENCES
1. Hoang N, Buchanan JA, Scherer SW. Heterogeneity in clinical sequencing tests marketed for autism spectrum disorders. NPJ Genom Med 2018;3:27.
2. Dias CM, Walsh CA. Recent advances in understanding the genetic architecture of autism. Annu Rev Genomics Hum Genet 2020;21:289-304.
3. Hertz-Picciotto I, Schmidt RJ, Krakowiak P. Understanding environmental contributions to autism: causal concepts and the state of science. Autism Res 2018;11:554-86.
4. Niesler B, Rappold GA. Emerging evidence for gene mutations driving both brain and gut dysfunction in autism spectrum disorder. Mol Psychiatry 2021;26:1442-4.
5. Ghrálaigh F, McCarthy E, Murphy DN, Gallagher L, Lopez LM. Brief report: evaluating the diagnostic yield of commercial gene panels in autism. J Autism Dev Disord 2022; doi: 10.1007/s10803-021-05417-7.
6. Zurita MF, Cárdenas PA, Sandoval ME, et al. Analysis of gut microbiome, nutrition and immune status in autism spectrum disorder: a case-control study in Ecuador. Gut Microbes 2020;11:453-64.
7. Myers SM, Challman TD, Bernier R, et al. Insufficient evidence for “autism-specific” genes. Am J Hum Genet 2020;106:587-95.
8. Lisik MZ, Gutmajster E, Sieroń AL. Anti-neuronal antibodies in patients with fragile X syndrome: is there a role of autoimmunity in its pathogenesis? Neurodegener Dis 2015;15:45-9.
9. Marco BD, Bonaccorso CM, Aloisi E, D'Antoni S, Catania MV. Neuro-inflammatory mechanisms in developmental disorders associated with intellectual disability and autism spectrum disorder: a neuro- immune perspective. CNS Neurol Disord Drug Targets 2016;15:448-63.
10. Barnhill K, Devlin M, Moreno HT, et al. Brief report: implementation of a specific carbohydrate diet for a child with autism spectrum disorder and fragile X syndrome. J Autism Dev Disord 2020;50:1800-8.
11. Nolan SO, Hodges SL, Binder MS, et al. Dietary rescue of adult behavioral deficits in the Fmr1 knockout mouse. PLoS One 2022;17:e0262916.
12. Napoli E, Schneider A, Wang JY, et al. Allopregnanolone treatment improves plasma metabolomic profile associated with gaba metabolism in fragile X-associated tremor/ataxia syndrome: a pilot study. Mol Neurobiol 2019;56:3702-13.
13. Song G, Napoli E, Wong S, et al. Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor/ataxia syndrome: use of antioxidants in precision medicine. Mol Med 2016;22:548-59.
14. Valenti D, de Bari L, De Filippis B, Henrion-Caude A, Vacca RA. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, Autism, Fragile X and Rett syndrome. Neurosci Biobehav Rev 2014;46 Pt 2:202-17.
15. Müller M. Disturbed redox homeostasis and oxidative stress: potential players in the developmental regression in Rett syndrome. Neurosci Biobehav Rev 2019;98:154-63.
16. Carlsson T, Rosenqvist M, Butwicka A, et al. Association of cumulative early medical factors with autism and autistic symptoms in a population-based twin sample. Transl Psychiatry 2022;12:73.
18. Volk HE, Ames JL, Chen A, et al. Considering toxic chemicals in the etiology of autism. Pediatrics 2022;149:e2021053012.
19. Bougeard C, Picarel-Blanchot F, Schmid R, Campbell R, Buitelaar J. Prevalence of autism spectrum disorder and co-morbidities in children and adolescents: a systematic literature review. Front Psychiatry 2021;12:744709.
20. Leader G, Abberton C, Cunningham S, et al. Gastrointestinal symptoms in autism spectrum disorder: a systematic review. Nutrients 2022;14:1471.
21. Isaksson J, Ruchkin V, Aho N, Lundin Remnélius K, Marschik PB, Bölte S. Nonshared environmental factors in the aetiology of autism and other neurodevelopmental conditions: a monozygotic co-twin control study. Mol Autism 2022;13:8.
22. Wei H, Zhu Y, Wang T, Zhang X, Zhang K, Zhang Z. Genetic risk factors for autism-spectrum disorders: a systematic review based on systematic reviews and meta-analysis. J Neural Transm 2021;128:717-34.
23. David MM, Enard D, Ozturk A, et al. Comorbid analysis of genes associated with autism spectrum disorders reveals differential evolutionary constraints. PLoS One 2016;11:e0157937.
24. Diaz-Beltran L, Esteban FJ, Varma M, et al. Cross-disorder comparative analysis of comorbid conditions reveals novel autism candidate genes. BMC Genomics 2017;18:1-14.
25. Klein L, D'Urso S, Eapen V, Hwang LD, Lin PI. Exploring polygenic contributors to subgroups of comorbid conditions in autism spectrum disorder. Sci Rep 2022;12:3416.
26. Ferreira ML, Loyacono N. Rationale of an advanced integrative approach applied to autism spectrum disorder: review, discussion and proposal. J Pers Med 2021;11:514.
27. Cawthorpe D. A 16-year cohort analysis of autism spectrum disorder-associated morbidity in a pediatric population. Front Psychiatry 2018;9:635.
28. Ozonoff S, Gangi D, Hanzel EP, et al. Onset patterns in autism: variation across informants, methods, and timing. Autism Res 2018;11:788-97.
29. Rose S, Niyazov DM, Rossignol DA, Goldenthal M, Kahler SG, Frye RE. Clinical and molecular characteristics of mitochondrial dysfunction in autism spectrum disorder. Mol Diagn Ther 2018;22:571-93.
30. Goncalves MVM, Harger R, Braatz V, et al. Pediatric acute-onset neuropsychiatric syndrome (PANS) misdiagnosed as autism spectrum disorder. Immunol Lett 2018;203:52-3.
31. Shulyakova N, Andreazza AC, Mills LR, Eubanks JH. Mitochondrial dysfunction in the pathogenesis of rett syndrome: implications for mitochondria-targeted therapies. Front Cell Neurosci 2017;11:58.
32. Kreiman BL, Boles RG. State of the art of genetic testing for patients with autism: a practical guide for clinicians. Semin Pediatr Neurol 2020;34:100804.
33. Stafford CF, Sanchez-Lara PA. Impact of genetic and genomic testing on the clinical management of patients with autism spectrum disorder. Genes 2022;13:585.
34. Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. Lancet Psychiatry 2015;2:909-16.
35. Shimizu H, Morimoto Y, Yamamoto N, Tayama T, Ozawa H, Imamura A. Overlap between epilepsy and neurodevelopmental disorders: insights from clinical and genetic studies. In: Czuczwar SJ, editor. Epilepsy. Exon Publications; 2022. pp. 41-54.
36. Frye RE, Casanova MF, Fatemi SH, et al. Neuropathological mechanisms of seizures in autism spectrum disorder. Front Neurosci 2016;10:192.
37. Frye RE. Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder. Epilepsy Behav 2015;47:147-57.
38. Kuo SS, van der Merwe C, Fu JM, et al. Developmental variability in autism across 17 000 autistic individuals and 4000 siblings without an autism diagnosis: comparisons by cohort, intellectual disability, genetic etiology, and age at diagnosis. JAMA Pediatr 2022;176:915-23.
39. Mpoulimari I, Zintzaras E. Synthesis of genetic association studies on autism spectrum disorders using a genetic model-free approach. Psychiatr Genet 2022;32:91-104.
40. Doi M, Li M, Usui N, Shimada S. Genomic strategies for understanding the pathophysiology of autism spectrum disorder. Front Mol Neurosci 2022;15:930941.
41. Casanova MF, Frye RE, Gillberg C, Casanova EL. Editorial: comorbidity and autism spectrum disorder. Front Psychiatry 2020;11:617395.
42. Autistica. Personal tragedies, public crisis. Available from: https://www.autistica.org.uk/downloads/files/Personal-tragedies-public-crisis-ONLINE.pdf [Last accessed on 27 Dec 2022].
43. Wills J, Evans Y. Health and service provision for people with autism spectrum disorders: a survey of parents in the United Kingdom. Available from: https://www.thinkingautism.org.uk/wp-content/uploads/Health__Service_Provision_for_People_with_ASD_March2016.pdf [Last accessed on 27 Dec 2022].
44. Lord C, Charman T, Havdahl A. The Lancet Commission on the future of care and clinical research in autism. Lancet Comm 2021;399:271-334.
45. Qiu S, Qiu Y, Li Y, Cong X. Genetics of autism spectrum disorder: an umbrella review of systematic reviews and meta-analyses. Transl Psychiatry 2022;12:249.
46. Panisi C, Guerini FR, Abruzzo PM, et al. Autism spectrum disorder from the womb to adulthood: suggestions for a paradigm shift. J Pers Med 2021 ;11:70.
47. MDPI. Special issue “a personalized medicine approach to the diagnosis and management of autism spectrum disorder”. Available from: https://www.mdpi.com/journal/jpm/special_issues/Personalized_Medicine_Approach_ASD [Last accessed on 27 Dec 2022].
48. MDPI. Special issue “a personalized medicine approach to the diagnosis and management of autism spectrum disorder: 2022”. Available from: https://www.mdpi.com/journal/jpm/special_issues/asd_personalized [Last accessed on 27 Dec 2022].
49. Whiteley P, Marlow B, Kapoor RR, Blagojevic-Stokic N, Sala R. Autoimmune encephalitis and autism spectrum disorder. Front Psychiatry 2021;12:775017.
50. Whiteley P, Carr K, Shattock P. Research, clinical, and sociological aspects of autism. Front Psychiatry 2021;12:481546.
51. Chen YJ, Duku E, Georgiades S. Rethinking autism intervention science: a dynamic perspective. Front Psychiatry 2022;13:827406.
52. Erbescu A, Papuc SM, Budisteanu M, Arghir A, Neagu M. Re-emerging concepts of immune dysregulation in autism spectrum disorders. Front Psychiatry 2022;13:1006612.
53. Jensen AR, Lane AL, Werner BA, McLees SE, Fletcher TS, Frye RE. Modern biomarkers for autism spectrum disorder: future directions. Mol Diagn Ther 2022;26:483-95.
55. Paulsen B, Velasco S, Kedaigle AJ, et al. Autism genes converge on asynchronous development of shared neuron classes. Nature 2022;602:268-73.
56. Shen L, Zhang H, Lin J, et al. A combined proteomics and metabolomics profiling to investigate the genetic heterogeneity of autistic children. Mol Neurobiol 2022;59:3529-45.
57. Roe K. Autism spectrum disorder initiation by inflammation-facilitated neurotoxin transport. Neurochem Res 2022;47:1150-65.
58. Ohashi K, Fukuhara S, Miyachi T, et al. Comprehensive genetic analysis of non-syndromic autism spectrum disorder in clinical settings. J Autism Dev Disord 2021;51:4655-62.
59. Yu KH, Palmer N, Fox K, et al. The phenotypical implications of immune dysregulation in fragile X syndrome. Eur J Neurol 2020;27:590-3.
